The DUSP23 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the human 786-O renal cell adenocarcinoma line. This polyclonal knockout pool provides a heterogeneous loss-of-function model for investigating DUSP23’s regulatory roles in MAPK signal transduction, cell cycle control, and stress responses, while avoiding clonal artifacts.
The 786-O cell line was established from a primary clear cell renal cell carcinoma (ccRCC) and carries a biallelic VHL mutation, a hallmark genetic lesion in the majority of sporadic ccRCC cases. This mutation results in constitutive activation of hypoxia-inducible factor (HIF) pathways, driving tumorigenic processes such as angiogenesis, metabolic reprogramming, and proliferation. As a well-characterized renal carcinoma epithelial model, 786-O cells are widely employed to dissect signaling networks and therapeutic responses in kidney cancer.
DUSP23 is a dual-specificity phosphatase that catalyzes the removal of phosphate groups from phosphotyrosine and phosphoserine/threonine residues on its substrates. It specifically targets the stress-activated MAP kinases JNK and p38, which are activated through a phosphorylation cascade. Upstream MAP3Ks, such as ASK1 and MEKK1, phosphorylate and activate MAP2Ks: MKK4 and MKK7 for JNK, and MKK3 and MKK6 for p38. These MAP2Ks then phosphorylate the TXY motifs of JNK and p38, leading to their activation. Once activated, JNK and p38 translocate to the nucleus where they phosphorylate transcription factors like c-Jun, ATF2, and ELK1, thereby promoting the expression of genes involved in cell proliferation, survival, and stress responses. DUSP23 physically interacts with JNK and p38, removing the activating phosphates to terminate signaling and maintain cellular homeostasis.
In the context of 786-O cells, loss of DUSP23 function may unleash JNK/p38 signaling, potentially driving unchecked proliferation, enhanced survival, and apoptotic resistance, all hallmarks of ccRCC progression. The VHL-mutant background of these cells, which already exhibits dysregulated hypoxia signaling, may synergize with elevated MAPK activity to promote tumorigenesis. Therefore, investigating DUSP23 in this model is critical for understanding how dual-specificity phosphatases act as tumor suppressors in renal carcinoma and for identifying novel therapeutic targets within the JNK/p38 axis.
This polyclonal DUSP23 knockout cell population is ideally suited for a broad range of functional studies. Researchers can employ Western blotting to quantify changes in phospho-JNK and phospho-p38 levels, and RT-qPCR to assess the expression of downstream targets such as c-Jun and ATF2. Proliferation assays (e.g., MTT or BrdU) and migration/invasion assays (wound healing or Transwell) enable the assessment of phenotypic consequences of DUSP23 loss. Co-immunoprecipitation can be used to confirm DUSP23 interaction with JNK or p38, while in vitro dephosphorylation assays may validate substrate specificity. Furthermore, these cells allow drug sensitivity profiling to explore resistance to chemotherapeutics or targeted agents, and RNA-seq transcriptomic analysis can uncover global gene expression changes. For additional product information or technical support, please contact Ascent Research.
